a Scientific and Medical Affairs Department , Sanofi Pasteur Inc ., Discovery Drive, Swiftwater , PA , USA.
b Clinical Development Department , Sanofi Pasteur Inc ., Swiftwater , PA , USA.
Expert Rev Vaccines. 2016 Oct;15(10):1245-53. doi: 10.1080/14760584.2016.1215246. Epub 2016 Aug 5.
An intradermal version of Fluzone® split-virion inactivated trivalent influenza vaccine, containing 9 µg hemagglutinin per strain of A/H1N1, A/H3N2, and one B lineage virus (Fluzone Intradermal, Sanofi Pasteur), became available in the US during the 2011-2012 influenza season for adults 18-64 years of age. In advance of the 2015-2016 season, Fluzone Intradermal was replaced with Fluzone Intradermal Quadrivalent vaccine, which contains 9 µg hemagglutinin per strain of the two A-strain viruses and both B-strain lineage viruses (Victoria and Yamagata).
This literature review summarizes the history and mechanism of intradermal vaccination, discusses the clinical trial results supporting the immunogenicity and safety of Fluzone Intradermal Quadrivalent vaccine, and describes the unique microinjection system used to deliver Fluzone Intradermal Quadrivalent. Expert commentary: Fluzone Intradermal Quadrivalent may boost confidence in influenza vaccination with the addition of a second B-lineage strain. By using an innovative microinjection system, the vaccine is also designed to address some of the logistic challenges faced by healthcare providers administering immunizations.
在 2011-2012 流感季节，美国推出了含有 9µg 血凝素/株的三价流感病毒裂解疫苗（Fluzone 分裂病毒，赛诺菲巴斯德）的皮内剂型，用于 18-64 岁成年人。在 2015-2016 流感季节之前，Fluzone 皮内剂型被 Fluzone 四价皮内疫苗取代，该疫苗含有每株 A 株病毒和两种 B 株系病毒（维多利亚和 Yamagata）的 9µg 血凝素。
本文综述了皮内接种的历史和机制，讨论了支持 Fluzone 皮内四价疫苗免疫原性和安全性的临床试验结果，并描述了用于递送 Fluzone 皮内四价疫苗的独特微注射系统。专家评论：Fluzone 皮内四价疫苗可能会通过增加第二种 B 谱系菌株来增强对流感疫苗接种的信心。通过使用创新的微注射系统，该疫苗还旨在解决医疗保健提供者在接种疫苗时面临的一些后勤挑战。
